EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS

Tadakazu Hisamatsu  ¹     Hyo Jong Kim  ²     Satoshi Motoya  ³     Yasuo Suzuki  ⁴     Yoshifumi Ohnishi  ⁵     Colleen W. Marano  ⁶     Yuya Imai  ⁷     Carine Saadoun  ⁸     Jianmin Zhuo  ⁹     Shiho Kawamura  ^9    
1 Kyorin University School of Medicine, Tokyo, Japan
² Kyung Hee University College of Medicine, Seoul, Korea (Republic of)
³ Sapporo-Kosei General Hospital, Hokkaido, Japan
⁴ Toho University Sakura Medical Center, Sakura, Japan
⁵ Shizuoka Medical Center, Shizuoka, Japan
⁶ Janssen Research & Development, LLC, Spring House
⁷ Janssen Pharmaceutical K.K., Tokyo, Japan
⁸ Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore
⁹ Janssen China Research & Development, Shanghai

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)